Rangaraj Narayanan

755 total citations
15 papers, 262 citations indexed

About

Rangaraj Narayanan is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, Rangaraj Narayanan has authored 15 papers receiving a total of 262 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 5 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Rangaraj Narayanan's work include Pharmacogenetics and Drug Metabolism (5 papers), Drug Transport and Resistance Mechanisms (2 papers) and Acute Myeloid Leukemia Research (1 paper). Rangaraj Narayanan is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Drug Transport and Resistance Mechanisms (2 papers) and Acute Myeloid Leukemia Research (1 paper). Rangaraj Narayanan collaborates with scholars based in United States, Switzerland and Germany. Rangaraj Narayanan's co-authors include David A. Williams, Barbara W. LeDuc, Manthena V. S. Varma, Vaishali Dixit, Kenichi Umehara, Felix Huth, Xiaoyan Chu, Jan Snoeys, Ming Zheng and Masanori Nakakariya and has published in prestigious journals such as Journal of the American Society of Nephrology, Journal of Pharmacology and Experimental Therapeutics and Life Sciences.

In The Last Decade

Rangaraj Narayanan

15 papers receiving 259 citations

Peers

Countries citing papers authored by Rangaraj Narayanan

Since Specialization

Citations

This map shows the geographic impact of Rangaraj Narayanan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rangaraj Narayanan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rangaraj Narayanan more than expected).

Fields of papers citing papers by Rangaraj Narayanan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rangaraj Narayanan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rangaraj Narayanan. The network helps show where Rangaraj Narayanan may publish in the future.

Co-authorship network of co-authors of Rangaraj Narayanan

This figure shows the co-authorship network connecting the top 25 collaborators of Rangaraj Narayanan. A scholar is included among the top collaborators of Rangaraj Narayanan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rangaraj Narayanan. Rangaraj Narayanan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients With IgA Nephropathy 2022 ·Journal of the American Society of Nephrology ·Jonathan Barratt, Laura Kooienga, Irfan Agha, (unknown), Biruh Workeneh, Sai Prasad N. Iyer, Rangaraj Narayanan, (unknown), Bess Sorensen, Brian S. Schwartz, Andrew J. King	2
2	Supplemental Insulin-Like Growth Factor-1 and Necrotizing Enterocolitis in Preterm Pigs 2021 ·Frontiers in Pediatrics ·(unknown), Xiaoyan Gao, Rangaraj Narayanan, Tripti Gaur, Galen Carey, Norman W. Barton, Xiaoyu Pan, (unknown), Thomas Thymann, Per Torp Sangild	18
3	Leveraging Quantitative Systems Pharmacology Approach into Development of Human Recombinant Follistatin Fusion Protein for Duchenne Muscular Dystrophy 2020 ·CPT Pharmacometrics & Systems Pharmacology ·Hoa Q. Nguyen, (unknown), David E. Ehmann, Paul Jasper, Bob Zhang, Haojing Rong, Devin Welty, Rangaraj Narayanan	7
4	Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations 2019 ·Clinical Pharmacology & Therapeutics ·Kunal S. Taskar, Venkatesh Pilla Reddy, Howard Burt, Maria M. Posada, Manthena V. S. Varma, Ming Zheng, Mohammed Ullah, Arian Emami Riedmaier, Kenichi Umehara, Jan Snoeys, Masanori Nakakariya, Xiaoyan Chu, Maud Bénéton, Yuan Chen, Felix Huth, Rangaraj Narayanan, Dwaipayan Mukherjee, Vaishali Dixit, Yuichi Sugiyama, Sibylle Neuhoff	110
5	Potent Triazolopyridine Myeloperoxidase Inhibitors 2018 ·ACS Medicinal Chemistry Letters ·Nicholas R. Wurtz, Andrew Q. Viet, Scott A. Shaw, Andrew K. Dilger, (unknown), Javed Khan, (unknown), Rangaraj Narayanan, Gayani Fernando, (unknown), Xiaoqin Liu, Gregory Locke, Lisa M. Kopcho, Lynn M. Abell, Paul G. Sleph, Michael Basso, Lei Zhao, Ruth R. Wexler, Franck Duclos, Ellen K. Kick	19
6	Assessment of drug–drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase 2018 ·Xenobiotica ·Zeen Tong, Rangaraj Narayanan, Christian Atsriku, (unknown), Yan Li, Hong Liu, Xiaomin Wang, Sekhar Surapaneni	1
7	Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group 2016 ·Bioorganic & Medicinal Chemistry ·James R. Corte, Tianan Fang, Donald Pinto, Michael J. Orwat, Alan R. Rendina, Joseph M. Luettgen, Karen A. Rossi, Anzhi Wei, Vidhyashankar Ramamurthy, Joseph E. Myers, S. Sheriff, Rangaraj Narayanan, Timothy W. Harper, Joanna J. Zheng, Yixin Li, Dietmar Seiffert, Ruth R. Wexler, Mimi L. Quan	15
8	Application of a “Fit for Purpose” PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide 2016 ·Drug Metabolism Letters ·Rangaraj Narayanan, Matthew Hoffmann, Gondi Kumar, Sekhar Surapaneni	9
9	The Uremic Toxin Indoxyl-3-Sulfate Induces CYP1A2 In Primary Human Hepatocytes 2016 ·Drug Metabolism Letters ·Hong Liu, Rangaraj Narayanan, Matthew Hoffmann, Sekhar Surapaneni	12
10	Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors 2016 ·ACS Medicinal Chemistry Letters ·Jeremy M. Richter, Daniel L. Cheney, (unknown), Anzhi Wei, Joseph M. Luettgen, Alan R. Rendina, (unknown), Rangaraj Narayanan, Pancras C. Wong, Dietmar Seiffert, Ruth R. Wexler, E. Scott Priestley	6
11	Pharmacological Characterization of a Novel Liver X Receptor Agonist with Partial LXRα Activity and a Favorable Window in Nonhuman Primates 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Todd G. Kirchgessner, Richard Martin, Paul G. Sleph, (unknown), Xiaoqin Liu, John A. Lupisella, (unknown), Rangaraj Narayanan, Yinong Xie, Jacek Ostrowski, Glenn H. Cantor, Raju Mohan, Ellen K. Kick	25
12	Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents 2009 ·Bioorganic & Medicinal Chemistry Letters ·Saleem Ahmad, Khehyong Ngu, Keith J. Miller, Ginger Wu, (unknown), (unknown), Ge Zhang, (unknown), (unknown), Mary Jane Cullen, Kenneth W. Rohrbach, Michael A. Thomas, (unknown), (unknown), Jinping Gan, Rangaraj Narayanan, Mary Ann Pelleymounter, Jeffrey A. Robl	13
13	Development and validation of a liquid chromatography–tandem mass spectrometric method for the determination of α-methyltyrosine in human plasma 2004 ·Journal of Chromatography B ·(unknown), Kenneth J. Ruterbories, (unknown), Rangaraj Narayanan	4
14	Glucuronidation of haloperidol by rat liver microsomes: involvement of family 2 UDP-glucuronosyltransferases 2004 ·Life Sciences ·Rangaraj Narayanan, Barbara W. LeDuc, David A. Williams	7
15	Determination of the kinetics of rat UDP-glucuronosyltransferases (UGTs) in liver and intestine using HPLC 2000 ·Journal of Pharmaceutical and Biomedical Analysis ·Rangaraj Narayanan, Barbara W. LeDuc, David A. Williams	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact